ARG41299
anti-PIAS1 + PIAS2 antibody
anti-PIAS1 + PIAS2 antibody for Flow cytometry,ICC/IF,IHC-Formalin-fixed paraffin-embedded sections,Immunoprecipitation,Western blot and Human,Mouse,Rat
Overview
| Product Description | Rabbit Polyclonal antibody recognizes PIAS1 + PIAS2 |
|---|---|
| Tested Reactivity | Hu, Ms, Rat |
| Tested Application | FACS, ICC/IF, IHC-P, IP, WB |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Target Name | PIAS1 + PIAS2 |
| Antigen Species | Human |
| Immunogen | Synthetic peptide derived from Human PIAS1 + PIAS2. |
| Conjugation | Un-conjugated |
| Alternate Names | PIAS1: Protein inhibitor of activated STAT protein 1; EC 6.3.2.-; Gu-binding protein; DEAD/H box-binding protein 1; E3 SUMO-protein ligase PIAS1; DDXBP1; GBP; RNA helicase II-binding protein; ZMIZ3; GU/RH-II PIAS2: Miz1; Protein inhibitor of activated STAT x; Protein inhibitor of activated STAT2; MIZ1; EC 6.3.2.-; PIASX-ALPHA; SIZ2; PIASX-BETA; ARIP3; DAB2-interacting protein; E3 SUMO-protein ligase PIAS2; MIZ; Androgen receptor-interacting protein 3; PIAS-NY protein; PIASX; DIP; Msx-interacting zinc finger protein; ZMIZ4 |
Application Instructions
| Application Suggestion |
|
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Application Note | * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. |
Properties
| Form | Liquid |
|---|---|
| Purification | Affinity purified |
| Buffer | PBS (pH 7.4), 150 mM NaCl, 0.02% Sodium azide and 50% Glycerol. |
| Preservative | 0.02% Sodium azide |
| Stabilizer | 50% Glycerol |
| Storage Instruction | For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. |
| Note | For laboratory research only, not for drug, diagnostic or other use. |
Bioinformation
| Gene Symbol | PIAS1; PIAS2 |
|---|---|
| Gene Full Name | protein inhibitor of activated STAT, 1; protein inhibitor of activated STAT, 2 |
| Background | PIAS1: This gene encodes a member of the mammalian PIAS [protein inhibitor of activated STAT-1 (signal transducer and activator of transcription-1)] family. This member contains a putative zinc-binding motif and a highly acidic region. It inhibits STAT1-mediated gene activation and the DNA binding activity, binds to Gu protein/RNA helicase II/DEAD box polypeptide 21, and interacts with androgen receptor (AR). It functions in testis as a nuclear receptor transcriptional coregulator and may have a role in AR initiation and maintenance of spermatogenesis. [provided by RefSeq, Jul 2008] PIAS2: This gene encodes a member of the protein inhibitor of activated STAT (PIAS) family. PIAS proteins function as SUMO E3 ligases and play important roles in many cellular processes by mediating the sumoylation of target proteins. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. Isoforms of the encoded protein enhance the sumoylation of specific target proteins including the p53 tumor suppressor protein, c-Jun, and the androgen receptor. A pseudogene of this gene is located on the short arm of chromosome 4. The symbol MIZ1 has also been associated with ZBTB17 which is a different gene located on chromosome 1. [provided by RefSeq, Aug 2011] |
| Function | PIAS1: Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. In vitro, binds A/T-rich DNA. The effects of this transcriptional coregulation, transactivation or silencing, may vary depending upon the biological context. Together with PRMT1, may repress STAT1 transcriptional activity, in the late phase of interferon gamma (IFN-gamma) signaling. Sumoylates PML (at'Lys-65' and 'Lys-160') and PML-RAR and promotes their ubiquitin-mediated degradation. PIAS1-mediated sumoylation of PML promotes its interaction with CSNK2A1/CK2 which in turn promotes PML phosphorylation and degradation (By similarity). Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation. Plays a dynamic role in adipogenesis by promoting the SUMOylation and degradation of CEBPB (By similarity). [UniProt] PIAS2: Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulator in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. The effects of this transcriptional coregulation, transactivation or silencing may vary depending upon the biological context and the PIAS2 isoform studied. However, it seems to be mostly involved in gene silencing. Binds to sumoylated ELK1 and enhances its transcriptional activity by preventing recruitment of HDAC2 by ELK1, thus reversing SUMO-mediated repression of ELK1 transactivation activity. Isoform PIAS2-beta, but not isoform PIAS2-alpha, promotes MDM2 sumoylation. Isoform PIAS2-alpha promotes PARK7 sumoylation. Isoform PIAS2-beta promotes NCOA2 sumoylation more efficiently than isoform PIAS2-alpha. Isoform PIAS2-alpha sumoylates PML at'Lys-65' and 'Lys-160'. [UniProt] |
| Cellular Localization | PIAS1: Nucleus speckle. Nucleus, PML body. Note=Interaction with CSRP2 may induce a partial redistribution along the cytoskeleton. [UniProt] PIAS2: Nucleus speckle. Nucleus, PML body. Nucleus. Note=Colocalizes at least partially with promyelocytic leukemia nuclear bodies (PML NBs) (PubMed:22406621). Colocalizes with SUMO1 in nuclear granules (By similarity). [UniProt] |
| Calculated MW | PIAS1: 72 kDa PIAS2: 68 kDa |
| PTM | PIAS1: Sumoylated. Dimethylated by PRMT1 at Arg-303 in the late phase of interferon gamma (IFN-gamma) signaling, leading to preferential interaction with STAT1 and thus resulting in release of STAT1 from its target gene. [UniProt] PIAS2: Sumoylated. [UniProt] |
Images (2) Click the Picture to Zoom In
-
ARG41299 anti-PIAS1 + PIAS2 antibody IHC-P image
Immunohistochemistry: Paraffin-embedded Human colon tissue stained with ARG41299 anti-PIAS1 + PIAS2 antibody.
-
ARG41299 anti-PIAS1 + PIAS2 antibody WB image
Western blot: HepG2 cell lysate stained with ARG41299 anti-PIAS1 + PIAS2 antibody.
